Nov 4, 7:30 AM ET
Arrowhead Pharmaceuticals refinanced its senior secured term loans on November 2, 2026, replacing a 15.0% payment-in-kind facility with a $400.0 million term loan at three-month Term SOFR plus 5.50% that matures November 2, 2031. The existing loans were repaid in full from cash on hand for an aggregate payoff of approximately $404.4 million, a discount of about $68 million from the 2.0x MOIC payment otherwise owed, and the new terms remove required prepayments from plozasiran sales and licensing proceeds. For shareholders, the filing shows lower interest cost, a longer maturity and fewer mandatory repayments, while the company now carries a $400.0 million secured obligation.
- New $400.0 million senior secured term loan matures November 2, 2031, with interest at three-month Term SOFR (1.00% floor) plus 5.50%, versus a fixed 15.0% rate paid in kind on the retired loans
- Existing loans repaid in full from cash on hand for an aggregate payoff of approximately $404.4 million, which included a discount of about $68 million from the 2.0x MOIC payment
- Minimum unrestricted cash covenant reduced to $125.0 million from $150.0 million
- New agreement no longer requires prepayment from plozasiran sales, royalties, milestones or pipeline monetizations; the filing says the terms are to be filed with the 10-Q for the quarter ended December 31, 2026
Read the filing on SEC.gov ↗
Aug 4, 4:03 PM ET
Arrowhead Pharmaceuticals reported fiscal third-quarter 2026 results for the period ended June 30, 2026. Revenue rose to $75.3 million from $27.8 million a year earlier, but the net loss attributable to Arrowhead widened to $194.3 million, or $1.36 per diluted share, from $175.2 million, or $1.26 per share, as research and development and selling, general and administrative expenses increased.
- Revenue was $75.3 million for the quarter, compared with $27.8 million in the prior-year quarter.
- Net loss attributable to Arrowhead was $194.3 million, or $1.36 per diluted share, versus $175.2 million, or $1.26 per share, a year earlier.
- Research and development expense was $198.2 million, up from $162.4 million, and SG&A expense was $47.1 million, up from $30.9 million.
- Total cash resources were $1.57 billion at June 30, 2026, compared with $781.5 million at September 30, 2025.
Read the filing on SEC.gov ↗
Jun 16, 4:02 PM ET
Arrowhead Pharmaceuticals appointed Dr. Matt Cohen as a director effective June 12, 2026, as disclosed in a June 16, 2026 Form 8-K. Dr. Cohen previously spent about two decades in healthcare investing and portfolio management, most recently as Managing Director at Vida Ventures, and his board seat adds a director with healthcare investment experience.
- Board appointment effective June 12, 2026
- Dr. Cohen is Managing Director at Vida Ventures and previously served at JP Morgan Asset Management from 2005
- Sign-on grant of restricted stock units valued at $887,000, scheduled to vest over three years
- Dr. Cohen will receive standard non-employee director compensation and enter the Company's standard indemnity agreement
Read the filing on SEC.gov ↗
May 7, 4:02 PM ET
Arrowhead Pharmaceuticals reported fiscal second-quarter results for the period ended March 31, 2026, with revenue of $73.7 million, down from $542.7 million a year earlier. The company posted a net loss attributable to Arrowhead of $132.7 million, or $0.93 per diluted share, compared with net income of $370.4 million, or $2.75 per diluted share, a year earlier. The filing also cites two concurrent public offerings with gross proceeds totaling $930 million.
- Revenue was $73.7 million for the quarter, versus $542.7 million in the same period a year earlier.
- Net loss attributable to Arrowhead was $132.7 million, or $0.93 per diluted share, versus net income of $370.4 million, or $2.75 per diluted share.
- Two concurrent offerings raised $930 million gross, including $700 million of 0.00% convertible senior notes due 2032 and $230 million of common stock at $64.50 per share.
- Research and development expense rose to $173.3 million from $133.1 million.
Read the filing on SEC.gov ↗
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.